|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2009-9-9
|
|
pubmed:abstractText |
Twice-weekly bortezomib has proven activity in mantle cell (MCL) and indolent lymphomas. This study explored a weekly schedule of bortezomib in follicular lymphoma (FL) and MCL. Although weekly bortezomib was better tolerated, the overall response rate (ORR) was inferior (18% vs. 50%, P = 0.02) with no complete remissions (CR) (compared with 18% CR for the twice-weekly schedule). Progression-free survival (PFS) was not different. The weekly schedule of bortezomib was less toxic, but yielded fewer and lower quality responses than twice-weekly bortezomib. Given the similar PFS, the weekly schedule may still be appropriate for some patients.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1365-2141
|
|
pubmed:author |
pubmed-author:CortelliBarbara MBM,
pubmed-author:DumitrescuOtiliaO,
pubmed-author:GerecitanoJohnJ,
pubmed-author:HamelersRachelR,
pubmed-author:HamlinPaulP,
pubmed-author:LinDorothyD,
pubmed-author:MoskowitzCraigC,
pubmed-author:NeylonEllenE,
pubmed-author:O'ConnorOwen AOA,
pubmed-author:PappanicholaouJenniferJ,
pubmed-author:PortlockCarolC,
pubmed-author:SarasohnDebraD,
pubmed-author:StrausDavidD,
pubmed-author:WrightJohnJ,
pubmed-author:ZelenetzAndrew DAD,
pubmed-author:ZhangZhigangZ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
146
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
652-5
|
|
pubmed:meshHeading |
pubmed-meshheading:19624539-Aged,
pubmed-meshheading:19624539-Aged, 80 and over,
pubmed-meshheading:19624539-Antineoplastic Agents,
pubmed-meshheading:19624539-Boronic Acids,
pubmed-meshheading:19624539-Disease-Free Survival,
pubmed-meshheading:19624539-Female,
pubmed-meshheading:19624539-Humans,
pubmed-meshheading:19624539-Lymphoma, Follicular,
pubmed-meshheading:19624539-Male,
pubmed-meshheading:19624539-Middle Aged,
pubmed-meshheading:19624539-Protease Inhibitors,
pubmed-meshheading:19624539-Pyrazines
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.
|
|
pubmed:affiliation |
Department of Medicine, Memorial Sloan Kettering Cancer Center, Columbia University, New York, NY 10021, USA. gerecitj@mskcc.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
